

**AURIS MEDICAL  
HOLDING AG,  
ZUG**

*Interim Balance Sheet for the Period  
Ended September 30, 2017 and Report  
of the Independent Auditor*

## Report of the independent auditor

To the Board of Directors of  
**Auris Medical Holding AG, Zug**

We have been appointed by the Board of Directors to examine the accompanying interim balance sheet of of Auris Medical Holding AG (the "Company") as of September 30, 2017. The interim balance sheet of the Company was prepared in accordance with Swiss Merger Act ("Fusionsgesetz" - FusG); article 11, para. 2 and the accounting, presentation and valuation principles stated in Swiss law applicable for annual financial statements.

### *Board of Directors' Responsibility*

The Board of Directors is responsible for the preparation of the interim balance sheet in accordance with the requirements of article 11, para. 2 FusG and the accounting, presentation and valuation principles in accordance with Swiss law applicable for annual financial statements. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of the interim balance sheet that is free from material misstatement, whether due to fraud or error.

### *Independent Auditor's Responsibility*

Our responsibility is to express an opinion on this interim balance sheet based on our examination. We conducted our examination in accordance with the Swiss audit guidance in the context of merger, splits, and conversions ("Schweizer Prüfungshinweis 30: Prüfungen nach dem Bundesgesetz über die Fusion, Spaltung, Umwandlung and Vermögensübertragung" - PH 30). This guidance requires that we comply with the ethical requirements, and that we plan and perform the examination to obtain limited assurance whether the interim balance sheet was prepared in accordance with article 11, para. 2 FusG and the accounting, presentation and valuation principles stated in Swiss law applicable for annual financial statements.

Our examination consists primarily of inquiries of company personnel and analytical procedures as well as detailed tests of company documents as considered necessary in the circumstances. However, the testing of operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## *Opinion*

Based on our examination, nothing has come to our attention that causes us to believe that the interim balance sheet is not prepared in accordance with article 11, para. 2 FusG and the accounting, presentation and valuation principles stated in Swiss law applicable for annual financial statements.

## **Deloitte AG**

Matthias Gschwend  
Licensed Audit Expert

Adrian Kaeppli  
Licensed Audit Expert

Zurich, January 29, 2018  
MGS/AKA/RMA

## Enclosures

- Interim balance sheet as at September 30, 2017

**AURIS MEDICAL HOLDING AG, ZUG**  
 INTERIM BALANCE SHEET AS AT SEPTEMBER 30, 2017

	30.09.2017 in CHF	31.12.2016 in CHF
<b>ASSETS</b>		
<b>Current assets</b>	<b>19'103'455</b>	<b>31'790'535</b>
<b>Cash and cash equivalents</b>	<b>19'016'421</b>	<b>31'556'105</b>
<b>Other short-term receivables</b>	<b>87'034</b>	<b>79'295</b>
Trade receivables third parties	84'069	79'295
Trade receivables group	2'965	-
<b>Prepaid expenses</b>	<b>-</b>	<b>155'135</b>
<b>Non-current assets</b>	<b>90'017'087</b>	<b>73'073'814</b>
<b>Other long-term receivables</b>	<b>79'916'930</b>	<b>62'973'657</b>
Intercompany loans, subordinated	79'916'930	62'973'657
<b>Investments in subsidiaries</b>	<b>10'100'157</b>	<b>10'100'157</b>
<b>TOTAL ASSETS</b>	<b>109'120'542</b>	<b>104'864'349</b>
<b>LIABILITIES AND EQUITY</b>		
<b>Current liabilities</b>	<b>5'499'526</b>	<b>3'588'505</b>
<b>Short-term payables</b>	<b>709'011</b>	<b>739'109</b>
Trade payables third parties	49'225	156'872
Trade payables group	659'786	582'237
<b>Other short-term payables</b>	<b>4'408'543</b>	<b>2'613'159</b>
Loan	4'406'208	2'590'857
Other payables	2'335	22'302
<b>Accrued expenses</b>	<b>381'971</b>	<b>236'237</b>
<b>Non-Current liabilities</b>	<b>7'362'537</b>	<b>10'886'981</b>
<b>Loan</b>	<b>6'666'787</b>	<b>10'154'143</b>
<b>Provision</b>	<b>695'750</b>	<b>732'838</b>
<b>Equity</b>	<b>96'258'480</b>	<b>90'388'863</b>
<b>Share capital</b>	<b>17'731'881</b>	<b>13'731'881</b>
<b>Legal capital reserves</b>	<b>120'570'367</b>	<b>114'879'634</b>
Reserves from capital contribution	114'671'822	114'671'822
Other capital reserve	5'898'545	207'812
<b>Accumulated deficit</b>	<b>-42'043'769</b>	<b>-38'222'652</b>
Loss for the year	-3'490'826	-3'393'256
Loss carryforward	-38'552'943	-34'829'396
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>109'120'542</b>	<b>104'864'349</b>